The withdrawal of the Form S-1 registration statement might be seen as a positive development by investors, indicating a potential strategic pivot or a change in financing strategy that could benefit the company's financial health. The announcement of an $8 million private placement suggests that Cyclacel Pharmaceuticals has secured an alternative funding route, which could support its operations and growth initiatives without diluting current shareholders' equity significantly. This combination of factors likely contributed to the positive market reaction.